



ACCESSUS HEALTH

A brand of **ECKER**  **ECKER**

In close collaboration
with EconMed –
Partner in the Project:



European HTA database

Access HTA procedures Europe-wide in one place –
for straightforward HTA Landscaping Across Europe

HTA Landscaping Across Europe


The Accessus Health European HTA database facilitates straightforward HTA landscaping across Europe, by offering fast and easy access to national and joint HTA procedures, all in one place. With country-specific data curated by local experts, it provides a comprehensive and up-to-date overview of relevant HTA and P&R documents, as available per country – to support you with preparation for EU HTA assessments and all European and local market access activities.

Scope

- Document database for HTA procedures from all European key markets (France, Germany, Italy and Spain already covered, and expanding for Europe-wide coverage)
- Documents on clinical evidence assessment, pricing & reimbursement, and health economic evaluations
- Both national and EU HTA procedures, for centrally authorized products (EMA)
- Monthly updates: coverage of the latest procedures and addition of historical data

Local expertise, common methodology

This central idea of the Accessus Health network also applies to the European HTA database: The data are curated by local network partners possessing country-specific HTA expertise, following one common methodology, in order to provide you with reliable, comprehensive HTA information across Europe.



Versatile search functionality to answer your specific questions

With its intuitive, flexible options for conducting, filtering, and displaying searches, the Accessus Health European HTA database can quickly provide you with information tailored to your individual needs – ranging from high-level scanning of available HTA procedures across Europe to systematic searches combining several specific aspects.

ACCESSUS HEALTH

Your account

Search

lymphoma

AND Enter search term

OR Enter search term

Therapeutic area (MeSH)

Select field (optional)

Select field (optional)

Select field (optional)

Procedure type

Language

Country/Region

Regulatory

Start year

End year

ATMP, Orphan Drug

2022

2025

Clear search

Search

Database Information



Support

Key functionalities of the database application

- Accessible anywhere and anytime: as a web application, the database is not bound to a specific device
- Intuitive navigation: Both simple and complex searches can be rapidly conducted via the easy-to-use interface, to quickly find HTA procedures and access the documents matching your questions.
- Targeted searches: a variety of combinable filters enables specific searches for HTA documents by, e.g., therapeutic area, country-specific reimbursement status, regulatory information, and many more.
- Flexibility and high sensitivity: optional full-text searches of all included HTA documents help to identify relevant documents even for rare cases, exceptional constellations, and special questions.

Search results

Displaying filtered search results: 18 HTA procedures, 58 documents

Year ↑↓	Country/ Region ↑↓	Language ↑↓	Procedure type ↑↓	Active substance ↑↓	Trade name ↑↓	Marketing authorization holder ↑↓	Therapeutic Area (MeSH) ↑↓	Reimbursement Status ↑↓		
>	2024	France	FR	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Follicular	with restrictions	Details
▼	2024	Spain	ES	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Follicular	with restrictions	Details
Documents for this procedure matching your query				Document type		Procedure type		Date	Language	Download
IPT: Yescarta (Axicabtagene ciloleucel) - Follicular lymphoma				National Therapeutic Positioning Report (IPT)		Clinical Evidence Assessment		Apr 27, 2024	ES	
CIPM resolution: Yescarta (Axicabtagene ciloleucel) - Follicular lymphoma				Resolution of the Interministerial Commission on Prices of Medicinal Products (CIPM)		Pricing & Reimbursement		Jan 29, 2024	ES	
>	2024	Germany	DE, EN	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Follicular	yes	Details
>	2024	Germany	DE	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Follicular	yes	Details
>	2024	Spain	ES	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Large B-Cell, Diffuse	with restrictions	Details
>	2024	Germany	DE	Clinical Evidence Assessment	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Large B-Cell, Diffuse	yes	Details
>	2023	Italy	IT	Pricing & Reimbursement	axicabtagene ciloleucel	Yescarta	Kite Pharma EU B.V.	Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular	yes	Details



Accessus Health offers Market Access services for all European markets. 250 local Market Access experts from our network of partner companies follow one common methodology.

#ToBeYourGatewayToEurope

Your contacts:

Janine Leismann Dr. Achim Löff Dr. Niels Mahrt

Please use our central mailbox to get in touch:
european-hta-database@accessus-health.eu